Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors

This study has been completed.
Information provided by (Responsible Party):
OncoMed Pharmaceuticals, Inc. Identifier:
First received: August 29, 2008
Last updated: September 16, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2012
  Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)